A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M, Chui MH, Zhou Q, Iasonos A, Sarasohn D, Cohen S, Friedman C, Grisham R, Konner J, Kyi C, Rubinstein M, Troso-Sandoval T, Aghajanian C, Makker V.
Lumish M, et al. Among authors: aghajanian c.
Gynecol Oncol. 2024 Mar;182:75-81. doi: 10.1016/j.ygyno.2023.12.028. Epub 2024 Jan 22.
Gynecol Oncol. 2024.
PMID: 38262242
Clinical Trial.